In a recent interview with the TRICHOMES Hash It Out podcast, they spoke with Front Range Biosciences' Co-founder and CEO, Dr. Jonathan Vaught, who discusses new developments in high-THCv cannabis varieties. Read an excerpt from the podcast:
"We knew early on from anecdotal evidence that THCv was a very exciting minor cannabinoid. So, we used our process to produce this compound at higher concentrations. With THCv, consumers report appetite suppression and energizing effects, similar to caffeine and tea, through a more clear-headed experience. Compounds like THCv present an incredible opportunity to bring new consumers to the market."
Listen to the podcast here.